Moreover, seminal studies demonstrated that a quiescent population of CML stem cells with BCR-ABL kinase domain mutation that is detectable before the initiation of IM therapy gives rise to leukemic cells that persist after treatment see references [1-7,49-52]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.